LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
SYDNEY, Australia, Aug. 20, 2017 -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima” or the “Company”) today announced that Grant Chamberlain will join the Board as a Non-Executive Director with immediate effect.
Mr Chamberlain brings extensive corporate finance and capital markets experience to Prima’s Board. Formerly Head of Mergers & Acquisitions and Financial Sponsors for Bank of America Merrill Lynch in Australia, Mr Chamberlain has more than twenty years experience in investment banking including former positions at Deutsche Bank and Nomura. He has advised major Australian and international companies on strategy, mergers and acquisitions and capital markets transactions.
Prima BioMed Chair Lucy Turnbull said: “We are delighted to welcome Grant to the Prima Board. His Australian and international markets experience will be a valuable asset as we progress our clinical development programs and consolidate our global leadership in LAG-3.”
Grant Chamberlain, on his appointment said: “I am honoured to join Prima’s Board. I have tremendous respect for Lucy and her fellow Directors and I’m excited about the potential of Prima’s LAG-3 technology. I look forward to contributing to Prima’s future success.”
About Prima BioMed
Prima BioMed is listed on the Australian Securities Exchange and on the NASDAQ in the US. For further information please visit www.primabiomed.com.au.
For further information please contact: U.S. Investors: Matthew Beck, The Trout Group LLC +1 (646) 378-2933; [email protected] Australian Investors/Media: Matthew Gregorowski, Citadel-MAGNUS +61 2 8234 0105; [email protected]
